Liver Biopsy Clinical Trial
Official title:
Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses
The investigators plan to compare complication and success rates between two methods of ultrasound guidance for biopsy of liver lesions, contrast-enhanced and the current protocol without contrast.
As a major oncology and hepatology center, the investigators perform about 3-5 guided
biopsies for liver tumors weekly. Ultrasound is the preferred modality for imaging biopsies
due to its ability to visualize and position the biopsy needle in real time with high
accuracy and safety, is nonionizing, and is quicker compared to other techniques, especially
CT-guided biopsies. The failure rate of ultrasound guided liver biopsies (including cases
where biopsy was declined to be performed due to lack of lesion visibility) is about 10%. By
comparison, in the investigators' practice genotyping of metastatic tumors, with multiple
core biopsies, is often requested for entry into oncology trials, and failure of tumor
genotyping after biopsy is estimated to be about 30%.
Recently, the first ultrasound contrast agent was FDA-approved for characterization of liver
lesions [sulfur hexafluoride lipid-type A microspheres (Lumason, Bracco Diagnostics, Monroe
Township, NJ)]. The microbubble agent is deemed safe, including in cardiac failure patients
and those with chronic airway obstruction. Injecting microbubbles may allow better
visualization of lesions and adjacent vasculature by enhancing the microvasculature and
adjacent vessels and potentially reduce incidence of failed biopsy or bleeding complications.
In addition, determination of necrotic regions in a lesion may allow better direction of
biopsy.
Yet there is limited literature on the use of ultrasound contrast agents for improving
targeted liver biopsies. The investigators intend to prospectively assess the non-diagnostic
biopsy and complication rates in a group of patients who undergo contrast-enhanced
ultrasonography (CEUS) using microbubbles at the time of biopsy. The investigators will then
compare the results from this group with the failure and complication rate from a control
group of patients undergoing the standard US-guided biopsy procedure. Over 12 months the
investigators expect to perform approximately 200 biopsies. Power analysis suggests that 125
patients in both contrast-enhanced sonography and control groups, each, are required. The
investigators should be able to enroll sufficient patients in 18 months
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00643656 -
Use of 50% Nitrous Oxide / 50% Oxygen Premix During Liver Biopsy of Focal Lesion
|
Phase 4 | |
Enrolling by invitation |
NCT04170452 -
Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta
|
||
Recruiting |
NCT03142698 -
Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis
|
N/A | |
Withdrawn |
NCT03910790 -
Liver Biopsy Using a 19 Gauge Fine Needle Biopsy Needle
|
N/A | |
Recruiting |
NCT03173287 -
Quantification of Hepatic Fibrosis by IVIM Sequences in 1.5T MRI
|
N/A | |
Completed |
NCT02620228 -
Identification of Liver Tumours Using BIP - Biopsy System
|
N/A | |
Completed |
NCT04003766 -
Endoscopic Ultrasound vs Percutaneous Route for Liver Biopsy
|
N/A | |
Terminated |
NCT02573545 -
Evaluation of a Support Software in the Planning and Real-time Monitoring of the Insertion of Needles in Interventional Magnetic Resonance Imaging (MRI): Liver Biopsy Case
|
N/A | |
Withdrawn |
NCT04039529 -
Novel Guidance Device for Image Fusion and Needle Guidance in Lung, Liver or Kidney Biopsy
|
N/A | |
Recruiting |
NCT05614973 -
Efficacy and Safety of Percutaneous Liver Biopsy With Needle Tract Plugging on Outpatient Basis
|
N/A |